Cochrane · systematic review · CD007961
Topical microbicides for preventing sexually transmitted infections
Obiero, J, Ogongo, P, Mwethera, PG, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
27
current version
GRADE rated
20
No studies
7
Included studies
NR
No studies 7 · 25.9%Ungraded 0 · 0%Very low 2 · 7.4%Low 16 · 59.3%Moderate 2 · 7.4%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyDapivirine vaginal microbicide for preventing sexually transmitted infections
Population: heterosexual women
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HIV infection | RR 0.71 [0.57, 0.89] | 2 studies · 4588 participants | Moderate Downgraded: imprecision |
Herpes simplex virus | no estimate extracted | NR | No studies |
Gonorrhoea | RR 1 [0.87, 1.15] | 2 studies · 4588 participants | Low Downgraded: imprecision, inconsistency |
Trichomoniasis | RR 1.06 [0.92, 1.23] | 2 studies · 4588 participants | Low Downgraded: imprecision |
Chlamydia | RR 0.97 [0.89, 1.07] | 2 studies · 4588 participants | Moderate Downgraded: inconsistency |
Syphilis | RR 1.7 [0.63, 4.59] | 1 study · 1956 participants | Low Downgraded: imprecision |
Serious adverse events | RR 1.12 [0.94, 1.32] | 2 studies · 4588 participants | Low Downgraded: imprecision, inconsistency |
Acceptability | no estimate extracted | NR | No studies |
Minor adverse events | no estimate extracted | NR | No studies |
Tenofovir vaginal microbicide for preventing sexually transmitted infections
Population: Heterosexual women
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HIV infection | RR 0.83 [0.68, 1.02] | 3 studies · 4958 participants | Low Downgraded: imprecision |
Herpes simplex virus | RR 0.9 [0.82, 0.99] | 2 studies · 2439 participants | Low Downgraded: inconsistency |
Gonorrhoea | RR 0.66 [0.4, 1.1] | 1 study · 2010 participants | Low Downgraded: imprecision |
Trichomoniasis | RR 1.21 [0.84, 1.74] | 1 study · 2010 participants | Low Downgraded: imprecision |
Chlamydia | RR 0.9 [0.71, 1.13] | 1 study · 2010 participants | Low Downgraded: imprecision |
Syphilis | RR 1.27 [0.58, 2.78] | 1 study · 2010 participants | Low Downgraded: imprecision |
Serious adverse events | RR 1 [0.81, 1.24] | 3 studies · 4958 participants | Very low Downgraded: imprecision, inconsistency |
Acceptability | no estimate extracted | NR | No studies |
Minor adverse events | no estimate extracted | NR | No studies |
Cellulose sulphate vaginal microbicide for preventing sexually transmitted infections
Population: Heterosexual women
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HIV Infection | RR 1.2 [0.74, 1.95] | 2 studies · 3069 participants | Low Downgraded: imprecision |
Herpes simplex | RR 0.99 [0.37, 2.62] | 1 study · 1425 participants | Low Downgraded: imprecision |
Gonorrhoea | RR 0.89 [0.67, 1.17] | 2 studies · 3069 participants | Very low Downgraded: imprecision, inconsistency |
Trichomoniasis | RR 0.96 [0.62, 1.49] | 1 study · 1425 participants | Low Downgraded: imprecision |
Chlamydia | RR 0.7 [0.49, 0.99] | 2 studies · 3069 participants | Low Downgraded: imprecision |
Syphilis | RR 0.69 [0.26, 1.81] | 1 study · 1425 participants | Low Downgraded: imprecision |
Serious adverse events | RR 1.25 [0.87, 1.79] | 2 studies · 3069 participants | Low Downgraded: imprecision |
Acceptability | no estimate extracted | NR | No studies |
Minor adverse events | no estimate extracted | NR | No studies |
Use of topical microbicides compared to placebo for preventing HIV and STIs
Population: Heterosexual women
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HIV infection Use of topical microbicides vs placebo | RR 0.93 [0.82, 1.05] | 8 studies · 24192 participants | Low |
Herpes simplex virus Use of topical microbicides vs placebo | RR 0.83 [0.67, 1.02] | 2 studies · 8502 participants | Low |
Gonorrhoea Use of topical microbicides vs placebo | RR 1.01 [0.88, 1.16] | 4 studies · 15921 participants | Low Downgraded: imprecision |
Chlamydia Use of topical microbicides vs placebo | RR 0.93 [0.83, 1.04] | 4 studies · 15922 participants | Low Downgraded: imprecision |
Syphilis Use of topical microbicides vs placebo | RR 1.01 [0.73, 1.41] | 2 studies · 7627 participants | Low Downgraded: imprecision |
Trichomoniasis Use of topical microbicides vs placebo | RR 0.86 [0.74, 1.01] | 2 studies · 7627 participants | Low Downgraded: imprecision |
Use of tenofovir vaginal microbicide compared to placebo for preventing HIV
Population: Heterosexual women
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HIV infection Use of tenofovir vaginal microbicide vs placebo | RR 0.63 [0.43, 0.93] | 1 study · 889 participants | Low |